Screener
ADMA Biologics ADMA SG&A
SG&A at other companies
Other financials
Where this comes from
Reported directly by ADMA Biologics in its filing.
Tagged under the XBRL concept us-gaap:SellingGeneralAndAdministrativeExpense.
The source filing: ADMA Biologics’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 5:16 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001140361-26-031445
| Line item | Three Months ended June 30, 2026 | Three Months ended June 30, 2025 | Six Months ended June 30, 2026 | Six Months ended June 30, 2025 |
|---|---|---|---|---|
| Plasma center operating expenses | 1,026 | 1,152 | 2,088 | 2,438 |
| Amortization of intangible assets | 55 | 32 | 110 | 57 |
| Gain on sale of plasma centers | - | - | (7,980) | - |
| Selling, general and administrative | 26,737 | 22,214 | 53,479 | 46,292 |
| Total operating expenses | 33,832 | 24,429 | 56,308 | 50,645 |
| INCOME FROM OPERATIONS | 52,445 | 42,798 | 110,719 | 77,678 |
| OTHER INCOME (EXPENSE): | ||||
| Interest and other income | 1,238 | 400 | 2,331 | 1,008 |
Item 1. Financial Statements.
FAQ
- What is ADMA Biologics's SG&A?
- ADMA Biologics (ADMA) reported SG&A of $26.74M in Q2 2026.
- How has ADMA Biologics's SG&A changed year-over-year?
- ADMA Biologics's SG&A increased by 20.4% year-over-year, from $22.21M to $26.74M.
- What is the long-term trend for ADMA Biologics's SG&A?
- Over 4 years (2021 to 2025), ADMA Biologics's SG&A has grown at a 20.9% compound annual growth rate (CAGR), from $42.9M to $91.58M.
- What does SG&A mean?
- Combined selling expenses (sales force, marketing, distribution) and general & administrative costs (management, legal, accounting, facilities) — the broadest opex category.
Ask your AI about ADMA Biologics's sg&a.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude